191 related articles for article (PubMed ID: 20605877)
21. TOLL-like receptor ligands stimulate aberrant class switch recombination in early B cell precursors.
Edry E; Azulay-Debby H; Melamed D
Int Immunol; 2008 Dec; 20(12):1575-85. PubMed ID: 18974086
[TBL] [Abstract][Full Text] [Related]
22. Emerging roles of TLR7 and TLR9 in murine SLE.
Santiago-Raber ML; Baudino L; Izui S
J Autoimmun; 2009; 33(3-4):231-8. PubMed ID: 19846276
[TBL] [Abstract][Full Text] [Related]
23. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9.
Wang D; Bhagat L; Yu D; Zhu FG; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2009 Jan; 52(2):551-8. PubMed ID: 19102653
[TBL] [Abstract][Full Text] [Related]
24. CpG DNA stimulates autoreactive immature B cells in the bone marrow.
Azulay-Debby H; Edry E; Melamed D
Eur J Immunol; 2007 Jun; 37(6):1463-75. PubMed ID: 17474151
[TBL] [Abstract][Full Text] [Related]
25. Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells.
Halcomb KE; Musuka S; Gutierrez T; Wright HL; Satterthwaite AB
Mol Immunol; 2008 Dec; 46(2):233-41. PubMed ID: 18849077
[TBL] [Abstract][Full Text] [Related]
26. Engagement of the B cell receptor for antigen differentially affects B cell responses to Toll-like receptor-7 agonists and antagonists in BXSB mice.
Layer T; Steele A; Goeken JA; Fleenor S; Lenert P
Clin Exp Immunol; 2011 Mar; 163(3):392-403. PubMed ID: 21235537
[TBL] [Abstract][Full Text] [Related]
27. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides.
Henault M; Lee LN; Evans GF; Zuckerman SH
J Immunol Methods; 2005 May; 300(1-2):93-9. PubMed ID: 15894327
[TBL] [Abstract][Full Text] [Related]
28. B-cell anergy is maintained in anti-DNA transgenic NZB/NZW mice.
Kat I; Makdasi E; Fischel R; Eilat D
Int Immunol; 2010 Feb; 22(2):101-11. PubMed ID: 20038519
[TBL] [Abstract][Full Text] [Related]
29. TLR4, TLR9 and MyD88 are not required for the positive selection of autoreactive B cells into the primary repertoire.
Silver K; Ferry H; Crockford T; Cornall RJ
Eur J Immunol; 2006 Jun; 36(6):1404-12. PubMed ID: 16703567
[TBL] [Abstract][Full Text] [Related]
30. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.
Lenert P; Yasuda K; Busconi L; Nelson P; Fleenor C; Ratnabalasuriar RS; Nagy PL; Ashman RF; Rifkin IR; Marshak-Rothstein A
Arthritis Res Ther; 2009; 11(3):R79. PubMed ID: 19476613
[TBL] [Abstract][Full Text] [Related]
31. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.
Leadbetter EA; Rifkin IR; Hohlbaum AM; Beaudette BC; Shlomchik MJ; Marshak-Rothstein A
Nature; 2002 Apr; 416(6881):603-7. PubMed ID: 11948342
[TBL] [Abstract][Full Text] [Related]
32. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.
Santiago-Raber ML; Dunand-Sauthier I; Wu T; Li QZ; Uematsu S; Akira S; Reith W; Mohan C; Kotzin BL; Izui S
J Autoimmun; 2010 Jun; 34(4):339-48. PubMed ID: 19944565
[TBL] [Abstract][Full Text] [Related]
33. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
Papadimitraki ED; Choulaki C; Koutala E; Bertsias G; Tsatsanis C; Gergianaki I; Raptopoulou A; Kritikos HD; Mamalaki C; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
[TBL] [Abstract][Full Text] [Related]
34. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
35. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
[TBL] [Abstract][Full Text] [Related]
36. TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase.
Séité JF; Guerrier T; Cornec D; Jamin C; Youinou P; Hillion S
J Autoimmun; 2011 Nov; 37(3):190-7. PubMed ID: 21689906
[TBL] [Abstract][Full Text] [Related]
37. Immunology. Discriminating microbe from self suffers a double toll.
Goodnow CC
Science; 2006 Jun; 312(5780):1606-8. PubMed ID: 16778043
[No Abstract] [Full Text] [Related]
38. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.
Yu D; Wang D; Zhu FG; Bhagat L; Dai M; Kandimalla ER; Agrawal S
J Med Chem; 2009 Aug; 52(16):5108-14. PubMed ID: 19650625
[TBL] [Abstract][Full Text] [Related]
39. Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients.
Rudnicka W; Burakowski T; Warnawin E; Jastrzebska M; Bik M; Kontny E; Chorazy-Massalska M; Radzikowska A; Buler M; Maldyk P; Maslinski W
Eur J Immunol; 2009 May; 39(5):1211-20. PubMed ID: 19384869
[TBL] [Abstract][Full Text] [Related]
40. Impact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.
Putta MR; Yu D; Bhagat L; Wang D; Zhu FG; Kandimalla ER
J Med Chem; 2010 May; 53(9):3730-8. PubMed ID: 20361743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
